Broom Daniel C, Jutkiewicz Emily M, Rice Kenner C, Traynor John R, Woods James H
Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-0632, USA.
Jpn J Pharmacol. 2002 Sep;90(1):1-6. doi: 10.1254/jjp.90.1.
The development of selective delta-opioid receptor agonists has revealed some very intriguing behavioral properties. delta-Opioid agonists have antinociceptive, seizuregenic and convulsive properties. A number of studies have identified a novel behavioral effect of delta-opioid-receptor agonists, implicating a role for the delta-opioid receptor in depression. Early clinical experiments demonstrated that exogenously administered opioid peptides had antidepressant activity in human patients. Also, enkephalinase inhibitors, which prevent the degradation of endogenous enkephalins, produced antidepressant-like effects mediated through the delta-opioid receptor in animal models of depression. More recently, the selective non-peptidic delta-opioid agonists SNC80 and (+)BW373U86 demonstrated antidepressant-like activity in the forced swim assay in rats. These studies propose that the delta-opioid receptor may provide a new therapeutic target for treating human depression.
选择性δ-阿片受体激动剂的研发揭示了一些非常有趣的行为特性。δ-阿片受体激动剂具有抗伤害感受、致癫痫和惊厥特性。多项研究已确定δ-阿片受体激动剂具有一种新的行为效应,这表明δ-阿片受体在抑郁症中发挥作用。早期临床实验表明,外源性给予的阿片肽在人类患者中具有抗抑郁活性。此外,可防止内源性脑啡肽降解的脑啡肽酶抑制剂,在抑郁症动物模型中产生了通过δ-阿片受体介导的类抗抑郁作用。最近,选择性非肽类δ-阿片受体激动剂SNC80和(+)BW373U86在大鼠强迫游泳试验中表现出类抗抑郁活性。这些研究表明,δ-阿片受体可能为治疗人类抑郁症提供一个新的治疗靶点。